Lung Cancer
V940-013- A Phase 2, randomized, double-blind, placebo-controlled study of V940 in combination with pembrolizumab and chemotherapy as first-line treatment for participants with metastatic squamous NSCLC (INTerpath-013)
- Details
ClinicalTrials.gov ID:
NCT07221474
Diagnosis Type:
NA
USOR Number:
- Address
,
P: